Marinus Pharmaceuticals
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch MRNS and buy or sell other stocks, ETFs, and their options commission-free!About MRNS
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
CEOAnders Edvell, MD, PhD
CEOAnders Edvell, MD, PhD
Employees—
Employees—
HeadquartersRadnor, Pennsylvania
HeadquartersRadnor, Pennsylvania
Founded2003
Founded2003
Employees—
Employees—
MRNS Key Statistics
Market cap29.63M
Market cap29.63M
Price-Earnings ratio-0.22
Price-Earnings ratio-0.22
Dividend yield—
Dividend yield—
Average volume333.56K
Average volume333.56K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$10.50
52 Week high$10.50
52 Week low$0.2202
52 Week low$0.2202
Stock Snapshot
Marinus Pharmaceuticals(MRNS) stock is priced at $0.55, giving the company a market capitalization of 29.63M. It carries a P/E multiple of -0.22.
On 2026-01-07, Marinus Pharmaceuticals(MRNS) shares started trading at —, with intraday highs of — and lows of —.
Trading activity shows a volume of 0, compared to an average daily volume of 333.56K.
The stock's 52-week range extends from a low of $0.22 to a high of $10.50.
The stock's 52-week range extends from a low of $0.22 to a high of $10.50.
People also own
Based on the portfolios of people who own MRNS. This list is generated using Robinhood data, and it’s not a recommendation.